Technology expertise, and support for gene therapy development

Gene therapies have the potential to treat once-incurable diseases.
But accelerating your gene therapy means optimizing workflows and scaling up while avoiding delays.

Our end-to-end workflows can help you set a course and sail to your next milestone, from bioreactor to process development to clinical trials and beyond. This information is for educational use.

Explore the workflow – hover over the products to learn more

Modalities

Adeno-associated viruses (AAV) for in vivo gene therapies

Lentiviruses for ex vivo gene therapies and CAR T cell therapies

Adenoviruses for oncolytic virus treatments and vaccines

Plasmids for transient transfection of viral vectors and templates for mRNA production

Exosomes for nonviral gene delivery

Discover how Cytiva can support your development and production needs across a variety of molecules and therapeutics.

Cell therapies
mRNA
mAbs
Protein research